Jefferies reiterates Collegium Pharmaceutical stock Buy on ADHD deal By Investing.com

Collegium agreed to acquire AZSTARYS for $650M cash plus up to $135M in milestones, with the company guiding to >$50M in second-half revenue from the acquisition and Jefferies calling for immediate EBITDA accretion and a path to >$500M EBITDA in 2026. Jefferies reiterated a Buy with a $51 target and Barclays kept an Overweight at $56 while the stock trades at $36.30 (analyst targets $44–$60). Collegium reported Q4 2025 EPS $2.04 (vs $2.14 est.) and revenue $205.45M (vs $207.07M est.), with LTM EBITDA of $419M and an 88% gross margin.

Analysis

The obvious winner is the acquirer’s commercial engine — a mid-sized specialty salesforce can convert an acquired ADHD franchise into outsized revenue per rep if execution is tight. Second-order beneficiaries include contract manufacturers and specialty distributors that can absorb incremental fill‑and‑finish volume, while legacy ADHD incumbents face share pressure where formulary slots are limited.

Key risks cluster around payor dynamics and execution. Payer formulary decisions and rebate negotiations can compress realized price within 6–12 months, and any bottleneck at fill/finish or packaging could push meaningful revenue back by a quarter or more; integration-driven SG&A synergies often take 9–18 months to materialize and are frequently overestimated.

Trade implementation should balance idiosyncratic upside with these operational risks. Short-duration options can express upside with controlled downside if you want leverage while a long equity position hedged with a biotech ETF short isolates product/capex execution; credit-sensitive moves (e.g., reducing buybacks to fund the deal) are a 12–24 month theme that could re-rate the equity if leverage increases materially.

Contrarian angle: the market is pricing mostly for upside from commercial cross‑sell but is underweight the scenario where payors force net pricing concessions that nullify the synergy case. Conversely, if integration is cleaner than peers historically achieve and formulary wins come faster, upside could compress timeline to positive free cash flow by multiple quarters, making a conviction long a crowded but rational play.

Key Decisions for Investors

• Long COLL equity on up to a 10% post‑announcement retracement; target +25% in 12 months, stop at -12% to control idiosyncratic execution risk.
• Buy a 12–18 month call spread on COLL (buy one 20% OTM, sell one 50% OTM) sized for 2–3% of portfolio to capture upside with defined loss; breakeven if upside materializes within 12–18 months.
• Pair trade: long COLL / short IBB (equal dollar) for 6–12 months to isolate company‑specific commercial execution versus broad biotech volatility; close if market breadth turns strongly positive or if COLL misses integration milestones.
• Monitor corporate credit and capital allocation: be prepared to trim equity exposure if net leverage increases meaningfully (e.g., leverage ratio step‑up within next 12 months) — this is a 12–24 month downside catalyst to protect against valuation multiple compression.